322 related articles for article (PubMed ID: 21915801)
81. Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer.
Laheurte C; Thiery-Vuillemin A; Calcagno F; Legros A; Simonin H; Boullerot L; Jacquin M; Nguyen T; Mouillet G; Borg C; Adotévi O
Int J Cancer; 2020 Aug; 147(4):1199-1205. PubMed ID: 31749145
[TBL] [Abstract][Full Text] [Related]
82. Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target.
Hashemi V; Maleki LA; Esmaily M; Masjedi A; Ghalamfarsa G; Namdar A; Yousefi M; Yousefi B; Jadidi-Niaragh F
Int Immunopharmacol; 2020 Jan; 78():106087. PubMed ID: 31841758
[TBL] [Abstract][Full Text] [Related]
83. Clinical relevance of regulatory T cells monitoring in the peripheral blood of ovarian cancer patients.
Brtnický T; Fialová A; Laštovička J; Rob L; Špíšek R
Hum Immunol; 2015 Mar; 76(2-3):187-91. PubMed ID: 25514665
[TBL] [Abstract][Full Text] [Related]
84. Metronomic cyclophosphamide: an alternative treatment for hepatic epithelioid hemangioendothelioma.
Lakkis Z; Kim S; Delabrousse E; Jary M; Nguyen T; Mantion G; Heyd B; Lassabe C; Borg C
J Hepatol; 2013 Jun; 58(6):1254-7. PubMed ID: 23402747
[TBL] [Abstract][Full Text] [Related]
85. Propranolol Attenuates Surgical Stress-Induced Elevation of the Regulatory T Cell Response in Patients Undergoing Radical Mastectomy.
Zhou L; Li Y; Li X; Chen G; Liang H; Wu Y; Tong J; Ouyang W
J Immunol; 2016 Apr; 196(8):3460-9. PubMed ID: 26969754
[TBL] [Abstract][Full Text] [Related]
86. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.
Muthu Raja KR; Rihova L; Zahradova L; Klincova M; Penka M; Hajek R
PLoS One; 2012; 7(10):e47077. PubMed ID: 23071717
[TBL] [Abstract][Full Text] [Related]
87. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.
Tongu M; Harashima N; Monma H; Inao T; Yamada T; Kawauchi H; Harada M
Cancer Immunol Immunother; 2013 Feb; 62(2):383-91. PubMed ID: 22926062
[TBL] [Abstract][Full Text] [Related]
88. Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response.
Heylmann D; Bauer M; Becker H; van Gool S; Bacher N; Steinbrink K; Kaina B
PLoS One; 2013; 8(12):e83384. PubMed ID: 24376696
[TBL] [Abstract][Full Text] [Related]
89. Low-dose metronomic chemotherapy with cisplatin enhanced immunity in a murine model of ectopic cervical cancer.
Tsai CC; Qiu JT; Tseng CW; Hsu YC
Clin Exp Pharmacol Physiol; 2016 Feb; 43(2):251-8. PubMed ID: 26541904
[TBL] [Abstract][Full Text] [Related]
90. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
Wu J; Jordan M; Waxman DJ
BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
[TBL] [Abstract][Full Text] [Related]
91. [Immunomodulation and antiangiogenesis in cancer therapy. From basic to clinical research].
Scharovsky OG; Matar P; Rozados VR; Rico MJ; Zacarías Fluck MF; Mainetti LE; Fernández Zenóbi MV; Roggero EA; Gervasoni SI; Rossa A; Perroud HA; Sánchez AM; Celoria GC; Font MT
Medicina (B Aires); 2012; 72(1):47-57. PubMed ID: 22257459
[TBL] [Abstract][Full Text] [Related]
92. Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed.
Abu Eid R; Razavi GS; Mkrtichyan M; Janik J; Khleif SN
Cancer Immunol Res; 2016 May; 4(5):377-82. PubMed ID: 27196429
[TBL] [Abstract][Full Text] [Related]
93. Long clinical benefit achieved in two patients with malignant paraganglioma treated by metronomic cyclophosphamide.
Gillon P; Godbert Y; Dupin C; Bubien V; Italiano A; Roubaud G
Future Oncol; 2014 Nov; 10(14):2121-5. PubMed ID: 25471026
[TBL] [Abstract][Full Text] [Related]
94. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.
Cerullo V; Diaconu I; Kangasniemi L; Rajecki M; Escutenaire S; Koski A; Romano V; Rouvinen N; Tuuminen T; Laasonen L; Partanen K; Kauppinen S; Joensuu T; Oksanen M; Holm SL; Haavisto E; Karioja-Kallio A; Kanerva A; Pesonen S; Arstila PT; Hemminki A
Mol Ther; 2011 Sep; 19(9):1737-46. PubMed ID: 21673660
[TBL] [Abstract][Full Text] [Related]
95. Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer.
McCaw TR; Goel N; Brooke DJ; Katre AA; Londoño AI; Smith HJ; Randall TD; Arend RC
Cancer Med; 2021 Jan; 10(2):709-717. PubMed ID: 33369199
[TBL] [Abstract][Full Text] [Related]
96. HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy.
Saraiva DP; Jacinto A; Borralho P; Braga S; Cabral MG
Front Immunol; 2018; 9():2605. PubMed ID: 30555458
[TBL] [Abstract][Full Text] [Related]
97. Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1.
Rathinasamy A; Domschke C; Ge Y; Böhm HH; Dettling S; Jansen D; Lasitschka F; Umansky L; Gräler MH; Hartmann J; Herold-Mende C; Schuetz F; Beckhove P
Cancer Immunol Immunother; 2017 May; 66(5):593-603. PubMed ID: 28224210
[TBL] [Abstract][Full Text] [Related]
98. CCR2 Influences T Regulatory Cell Migration to Tumors and Serves as a Biomarker of Cyclophosphamide Sensitivity.
Loyher PL; Rochefort J; Baudesson de Chanville C; Hamon P; Lescaille G; Bertolus C; Guillot-Delost M; Krummel MF; Lemoine FM; Combadière C; Boissonnas A
Cancer Res; 2016 Nov; 76(22):6483-6494. PubMed ID: 27680685
[TBL] [Abstract][Full Text] [Related]
99. Effective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer.
Chen X; Yang Y; Zhou Q; Weiss JM; Howard OZ; McPherson JM; Wakefield LM; Oppenheim JJ
PLoS One; 2014; 9(1):e85398. PubMed ID: 24416401
[TBL] [Abstract][Full Text] [Related]
100. Low dose cyclophosphamide: Mechanisms of T cell modulation.
Madondo MT; Quinn M; Plebanski M
Cancer Treat Rev; 2016 Jan; 42():3-9. PubMed ID: 26620820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
